
IRVINE, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2015 financial results, which will take place on Monday, February 22, 2016 after the close of the market.

Endologix will hold a conference call on Monday, February 22, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com.

After the live webcast, a replay of the webcast will remain available online from the investor relations page of Endologix's website, www.endologix.com, through February 22, 2017. In addition, a transcript will be posted to the website and a telephonic replay of the call will be available until February 29, 2016. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay pin number 13629814.

About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

ENDOLOGIX CONTACT:

Endologix, Inc.
John McDermott, CEO
Vaseem Mahboob, CFO
(949) 595-7200
www.endologix.com

INVESTOR CONTACTS:

The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020

Source: Endologix

News Provided by Acquire Media